April 05, 2024
2 min watch
Save
VIDEO: Aurion aims to end corneal endothelial disease with cell therapy
BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Greg Kunst, CEO of Aurion Biotech, discusses the company’s cell therapy for corneal endothelial disease.
Kunst said the company is nearing completion of its phase 1/2 trial, and recent data have provided valuable insight as Aurion moves into phase 3 trials and its commercialization strategy.
“We have a product that has been in over 130 subjects in our early trials,” he said. “We have a product that we can scale massively and really take this around the world to end the scourge of corneal endothelial disease.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Kunst reports being an employee of Aurion Biotech.
Read more about